Prime Medicine, Inc. (PRME)
2.98
-0.01
(-0.33%)
USD |
NASDAQ |
Oct 02, 16:00
3.00
+0.02
(+0.67%)
After-Hours: 20:00
Prime Medicine EPS Diluted (Quarterly) : -0.2376 for June 30, 2026
EPS Diluted (Quarterly) Chart
Historical EPS Diluted (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | -0.2376 |
| March 31, 2026 | -0.2774 |
| December 31, 2025 | -0.2553 |
| September 30, 2025 | -0.3152 |
| June 30, 2025 | -0.4071 |
| March 31, 2025 | -0.3965 |
| December 31, 2024 | -0.3565 |
| September 30, 2024 | -0.4385 |
| June 30, 2024 | -0.4642 |
| March 31, 2024 | -0.438 |
| December 31, 2023 | -0.6741 |
| September 30, 2023 | -0.5521 |
| Date | Value |
|---|---|
| June 30, 2023 | -0.4685 |
| March 31, 2023 | -0.4423 |
| December 31, 2022 | -0.4176 |
| September 30, 2022 | -0.3674 |
| June 30, 2022 | -0.3723 |
| March 31, 2022 | -0.314 |
| December 31, 2021 | -0.7236 |
| September 30, 2021 | -0.2379 |
| June 30, 2021 | -0.044 |
| March 31, 2021 | -0.9177 |
| December 31, 2020 | -0.035 |
EPS Diluted (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
EPS Diluted (Quarterly) Benchmarks
| Beam Therapeutics, Inc. | -1.176 |
| Twist Bioscience Corp. | -0.5617 |
| Intellia Therapeutics, Inc. | -0.7989 |
| Q32 Bio, Inc. | -0.4398 |
| Revolution Medicines, Inc. | -3.055 |
EPS Diluted (Quarterly) Related Metrics
| Net Income (Quarterly) | -42.11M |
| Revenue (Quarterly) | 1.154M |
| Total Expenses (Quarterly) | 43.26M |
| Enterprise Value | 556.00M |
| Gross Profit Margin (Quarterly) | -54.68% |
| Profit Margin (Quarterly) | -3.65K% |
| Earnings Yield | -36.43% |
| Normalized Earnings Yield | -36.70 |